EJHaem · 2025
Impact of Reduction in Myeloid-derived Suppressor Cells by Wilms' Tumor 1-targeted Dendritic Cell Vaccines on Clinical Outcomes in Acute Leukemia Patients.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ogasawara Masahiro, Miyashita Mamiko, Yamagishi Yuka, Ota Shuichi
Аннотация
BACKGROUND: Myeloid-derived suppressor cells (MDSCs) play a critical role in immunotherapy.
METHODS: We investigated the effects of the Wilms' tumor 1 (WT1) peptide-loaded dendritic cell (DC) vaccination on MDSCs in patients with acute leukemia.
RESULTS: WT1-DC vaccination reduced MDSCs and enhanced WT1-specific immunity. In complete remission patients, MDSC reduction was accompanied by decreased arginase 1 and indoleamine 2,3-dioxygenase levels and increased interleukin (IL)-12 and interferon-γ levels in plasma. Conversely, patients with disease progression showed increased IL-10 and transforming growth factor-β1. Reduced MDSCs were correlated with WT1-specific immune activation and associated with longer survival.
CONCLUSION: These findings indicate that WT1-DC vaccination suppresses MDSCs and improves clinical outcomes.
CLINICAL TRIAL REGISTRATION: This study is registered with the University Hospital Medical Information Network (UMIN) in Japan (Registration ID: UMIN000027279).
METHODS: We investigated the effects of the Wilms' tumor 1 (WT1) peptide-loaded dendritic cell (DC) vaccination on MDSCs in patients with acute leukemia.
RESULTS: WT1-DC vaccination reduced MDSCs and enhanced WT1-specific immunity. In complete remission patients, MDSC reduction was accompanied by decreased arginase 1 and indoleamine 2,3-dioxygenase levels and increased interleukin (IL)-12 and interferon-γ levels in plasma. Conversely, patients with disease progression showed increased IL-10 and transforming growth factor-β1. Reduced MDSCs were correlated with WT1-specific immune activation and associated with longer survival.
CONCLUSION: These findings indicate that WT1-DC vaccination suppresses MDSCs and improves clinical outcomes.
CLINICAL TRIAL REGISTRATION: This study is registered with the University Hospital Medical Information Network (UMIN) in Japan (Registration ID: UMIN000027279).